Disorders of sex development: Effect of molecular diagnostics

Nature Reviews Endocrinology

Volumn 11, Issue 8, 2015, Pages 478-488

  Achermann, John C ^a   Domenice, Sorahia ^b   Bachega, Tania A S S ^b   Nishi, Mirian Y ^b   Mendonca, Berenice B ^b  

^a UNIVERSITY COLLEGE LONDON   (United Kingdom)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

TESTOSTERONE;

5 ALPHA REDUCTASE DEFICIENCY; ANDROGEN INSENSITIVITY SYNDROME; COMPARATIVE GENOMIC HYBRIDIZATION; CONGENITAL ADRENAL HYPERPLASIA; COPY NUMBER VARIATION; DISORDER OF SEX DEVELOPMENT; DNA DETERMINATION; GENE SEQUENCE; GENETIC COUNSELING; GONADAL DISEASE; GOOD CLINICAL PRACTICE; HIGH THROUGHPUT SEQUENCING; HUMAN; MOLECULAR BIOLOGY; MOLECULAR DIAGNOSIS; MOLECULAR DIAGNOSTICS; NEXT GENERATION SEQUENCING; PRENATAL DIAGNOSIS; PRIORITY JOURNAL; REVIEW; SEX CHROMOSOME ABERRATION; STEROID 21 MONOOXYGENASE DEFICIENCY; TESTOSTERONE SYNTHESIS; XY GONADAL DYSGENESIS; DISORDERS OF SEX DEVELOPMENT; FEMALE; GENETIC SCREENING; GENETICS; MALE; MOLECULAR PATHOLOGY; NEWBORN;

DISORDERS OF SEX DEVELOPMENT; FEMALE; GENETIC TESTING; HUMANS; INFANT, NEWBORN; MALE; PATHOLOGY, MOLECULAR;

EID: 84937731374     PISSN: 17595029     EISSN: 17595037     Source Type: Journal    
DOI: 10.1038/nrendo.2015.69     Document Type: Review

References (115)

1. Eggers, S., Ohnesorg, T. & Sinclair, A. Genetic regulation of mammalian gonad development. Nat. Rev. Endocrinol. 10, 673-683 (2014
2. Hughes, I.A., Houk, C., Ahmed, S.F. & Lee, P.A. Consensus statement on management of intersex disorders. Arch. Dis. Child. 91, 554-563 (2006
3. Hsu, L.Y. Phenotype/karyotype correlations of Y chromosome aneuploidy with emphasis on structural aberrations in postnatally diagnosed cases. Am. J. Med. Genet. 53, 108-140 (1994
4. Griffin, J., McPhaul, M., Russell, D. & Wilson, J. in The Metabolic and Molecular Bases of Inherited Disease (eds Scriver, C.R. et al.) 2967-2979 (McGraw-Hill, 1995
5. De Marchi, M., Campagnoli, C., Ghiringhello, B., Ponzio, G. & Carbonara, A. Gonadal agenesis in a phenotypically normal female with positive H Y antigen. Hum. Genet. 56, 417-419 (1981
6. Berkovitz, G.D. et al. Clinical and pathologic spectrum of 46, XY gonadal dysgenesis: its relevance to the understanding of sex differentiation. Medicine (Baltimore) 70, 375-383 (1991
7. Eggers, S. & Sinclair, A. Mammalian sex determination-insights from humans and mice. Chromosome Res. 20, 215-238 (2012
8. Ahmed, S.F. et al. UK guidance on the initial evaluation of an infant or an adolescent with a suspected disorder of sex development. Clin. Endocrinol. (Oxf.) 75, 12-26 (2011
9. Ahmed, S.F. et al. Phenotypic features, androgen receptor binding, and mutational analysis in 278 clinical cases reported as androgen insensitivity syndrome. J. Clin. Endocrinol. Metab. 85, 658-665 (2000
10. McDonald, M.T., Flejter, W., Sheldon, S., Putzi, M.J. & Gorski, J.L. XY sex reversal and gonadal dysgenesis due to 9p24 monosomy. Am. J. Med. Genet. 73, 321-326 (1997
11. Baxter, R.M. & Vilain, E. Translational genetics for diagnosis of human disorders of sex development. Annu. Rev. Genomics Hum. Genet. 14, 371-392 (2013
12. Martin, R.M. et al. P450c17 deficiency in Brazilian patients: biochemical diagnosis through progesterone levels confirmed by CYP17 genotyping. J. Clin. Endocrinol. Metab. 88, 5739-5746 (2003
13. Mendonca, B.B. et al. Male pseudohermaphroditism due to 17β-hydroxysteroid dehydrogenase 3 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 79, 299-309 (2000
14. Barbaro, M. et al. Gene dosage imbalances in patients with 46, XY gonadal DSD detected by an in house designed synthetic probe set for multiplex ligation-dependent probe amplification analysis. Clin. Genet. 73, 453-464 (2008
15. Gundry, M. & Vijg, J. Direct mutation analysis by high-throughput sequencing: from germline to low-Abundant, somatic variants. Mutat. Res. 729, 1-15 (2012
16. Ledig, S. et al. Array-CGH analysis in patients with syndromic and non-syndromic XY gonadal dysgenesis: evaluation of array CGH as diagnostic tool and search for new candidate loci. Hum. Reprod. 25, 2637-2646 (2010
17. Tannour-Louet, M. et al. Identification of De novo copy number variants associated with human disorders of sexual development. PLoS ONE 5, e15392 (2010
18. Norling, A. et al. Novel candidate genes for 46, XY gonadal dysgenesis identified by a customized 1 M array-CGH platform. Eur. J. Med. Genet. 56, 661-668 (2013
19. Shinawi, M. & Cheung, S.W. The array CGH and its clinical applications. Drug Discov. Today 13, 760-770 (2008
20. White, S. et al. Copy number variation in patients with disorders of sex development due to 46, XY gonadal dysgenesis. PLoS ONE 6, e17793 (2011
21. MacArthur, D.G. et al. Guidelines for investigating causality of sequence variants in human disease. Nature 508, 469-476 (2014
22. Kingsmore, S.F. & Saunders, C.J. Deep sequencing of patient genomes for disease diagnosis: when will it become routine?. Sci. Transl. Med. 3, 87ps23 (2011
23. Swanson, A., Ramos, E. & Snyder, H. Next generation sequencing is the impetus for the next generation of laboratory-based genetic counselors. J. Genet. Couns. 23, 647-654 (2014
24. Bashamboo, A., Ledig, S., Wieacker, P., Achermann, J.C. & McElreavey, K. New technologies for the identification of novel genetic markers of disorders of sex development (DSD). Sex. Dev. 4, 213-224 (2010
25. Facio, F.M. et al. Intentions to receive individual results from whole-genome sequencing among participants in the ClinSeq study. Eur. J. Hum. Genet. 21, 261-265 (2013
26. Facio, F.M., Lee, K. & O-Daniel, J.M. A genetic counselor's guide to using next-generation sequencing in clinical practice. J. Genet. Couns. 23, 455-462 (2014
27. Biesecker, L.G. & Green, R.C. Diagnostic clinical genome and exome sequencing. N. Engl. J. Med. 370, 2418-2425 (2014
28. Strom, S.P. et al. Assessing the necessity of confirmatory testing for exome-sequencing results in a clinical molecular diagnostic laboratory. Genet. Med. 16, 510-515 (2014
29. Toledo, R.A. & Dahia, P.L. Next-generation sequencing for the genetic screening of phaeochromcytomas and paragangliomas: riding the new wave, but with caution. Clin. Endocrinol. (Oxf.) 80, 23-24 (2014
30. Facio, F.M., Lee, K. & O-Daniel, J.M. A genetic counselor's guide to using next-generation sequencing in clinical practice. J. Genet. Couns. 23, 455-462 (2013
31. Dorschner, M.O. et al. Actionable, pathogenic incidental findings in 1, 000 participants- exomes. Am. J. Hum. Genet. 93, 631-640 (2013
32. Baxter, R.M. et al. Exome sequencing for the diagnosis of 46, XY disorders of sex development. J. Clin. Endocrinol. Metab. 100, E333-E344 (2014
33. Katsanis, S.H. & Katsanis, N. Molecular genetic testing and the future of clinical genomics. Nat. Rev. Genet. 14, 415-426 (2013
34. Pinette, M.G., Wax, J.R., Blackstone, J. & Cartin, A. Normal growth and development of fetal external genitalia demonstrated by sonography. J. Clin. Ultrasound 31, 465-472 (2003
35. Pinhas-Hamiel, O. et al. Prenatal diagnosis of sex differentiation disorders: the role of fetal ultrasound. J. Clin. Endocrinol. Metab. 87, 4547-4553 (2002
36. Colmant, C., Morin-Surroca, M., Fuchs, F., Fernandez, H. & Senat, M.V. Non-invasive prenatal testing for fetal sex determination: is ultrasound still relevant?. Eur. J. Obstet. Gynecol. Reprod. Biol. 171, 197-204 (2013
37. Tabor, A., Vestergaard, C.H. & Lidegaard, O. Fetal loss rate after chorionic villus sampling and amniocentesis: an 11-year national registry study. Ultrasound Obstet. Gynecol. 34, 19-24 (2009
38. Mujezinovic, F. & Alfirevic, Z. Procedure-related complications of amniocentesis and chorionic villous sampling: a systematic review. Obstet. Gynecol. 110, 687-694 (2007
39. Lo, Y.M. et al. Presence of fetal DNA in maternal plasma and serum. Lancet 350, 485-487 (1997
40. Wright, C.F., Wei, Y., Higgins, J.P. & Sagoo, G.S. Non-invasive prenatal diagnostic test accuracy for fetal sex using cell-free DNA a review and meta-Analysis. BMC Res. Notes 5, 476 (2012
41. Devaney, S.A., Palomaki, G.E., Scott, J.A. & Bianchi, D.W. Noninvasive fetal sex determination using cell-free fetal DNA: a systematic review and meta-Analysis. JAMA 306, 627-636 (2011
42. Zimmermann, B.G., Holzgreve, W., Avent, N. & Hahn, S. Optimized real-time quantitative PCR measurement of male fetal DNA in maternal plasma. Ann. NY Acad. Sci. 1075, 347-349 (2006
43. Liu, F.M. et al. Feasibility study of using fetal DNA in maternal plasma for non-invasive prenatal diagnosis. Acta Obstet. Gynecol. Scand. 86, 535-541 (2007
44. Martinhago, C.D. et al. Accuracy of fetal gender determination in maternal plasma at 5 and 6 weeks of pregnancy. Prenat. Diagn. 26, 1219-1223 (2006
45. Hill, M., Barrett, A.N., White, H. & Chitty, L.S. Uses of cell free fetal DNA in maternal circulation. Best Pract. Res. Clin. Obstet. Gynaecol. 26, 639-654 (2012
46. Alvarez-Nava, F., Gonzalez, S., Soto, S., Pineda, L. & Morales-Machin, A. Mixed gonadal dysgenesis: a syndrome of broad clinical, cytogenetic and histopathologic spectrum. Genet. Couns. 10, 233-243 (1999
47. Ocal, G. et al. The clinical and genetic heterogeneity of mixed gonadal dysgenesis: does "disorders of sexual development (DSD)" classification based on new Chicago consensus cover all sex chromosome DSD?. Eur. J. Pediatr. 171, 1497-1502 (2012
48. Bagci, G., Acar, H. & Tomruk, H. Different chromosome Y abnormalities in Turner syndrome. Genet. Couns. 12, 255-261 (2001
49. Shinawi, M. et al. Mixed gonadal dysgenesis in a child with isodicentric Y chromosome: Does the relative proportion of the 45, X line really matter?. Am. J. Med. Genet. A 152A, 1832-1837 (2010
50. Prakash, S. et al. Single-nucleotide polymorphism array genotyping is equivalent to metaphase cytogenetics for diagnosis of Turner syndrome. Genet. Med. 16, 53-59 (2014
51. Hersmus, R. et al. SRY mutation analysis by next generation (deep) sequencing in a cohort of chromosomal disorders of sex development (DSD) patients with a mosaic karyotype. BMC Med. Genet. 13, 108 (2012
52. Lobaccaro, J.M. et al. Molecular prenatal diagnosis of partial androgen insensitivity syndrome based on the Hind III polymorphism of the androgen receptor gene. Clin. Endocrinol. (Oxf.) 40, 297-302 (1994
53. Bertelloni, S. et al. 17β-hydroxysteroid dehydrogenase 3 deficiency: from pregnancy to adolescence. J. Endocrinol. Invest. 32, 666-670 (2009
54. Richard, N. et al. Identification by array-comparative genomic hybridization (array-CGH) of a large deletion of luteinizing hormone receptor gene combined with a missense mutation in a patient diagnosed with a 46, XY disorder of sex development and application to prenatal diagnosis. Endocr. J. 58, 769-776 (2011
55. Russo, G. et al. 46, XY karyotype in a female phenotype fetus: a challenging diagnosis. J. Pediatr. Adolesc. Gynecol. 25, e77-e79 (2012
56. Ocal, G. Current concepts in disorders of sexual development. J. Clin. Res. Pediatr. Endocrinol. 3, 105-114 (2011
57. Pearlman, A. et al. Mutations in MAP3K1 cause 46, XY disorders of sex development and implicate a common signal transduction pathway in human testis determination. Am. J. Hum. Genet. 87, 898-904 (2010
58. Hutson, J.M., Grover, S.R., O-Connell, M. & Pennell, S.D. Malformation syndromes associated with disorders of sex development. Nat. Rev. Endocrinol. 10, 476-487 (2014
59. Lourenco, D. et al. Loss of function mutation in GATA4 causes anomalies of human testicular development. Proc. Natl Acad. Sci. USA 108, 1597-1602 (2013
60. Wagner, T. et al. Autosomal sex reversal and campomelic dysplasia are caused by mutations in and around the SRY-related gene SOX9. Cell 79, 1111-1120 (1994
61. Machado, A.Z. et al. Absence of inactivating mutations and deletions in the DMRT1 and FGF9 genes in a large cohort of 46, XY patients with gonadal dysgenesis. Eur. J. Med. Genet. 55, 690-694 (2012
62. Benko, S. et al. Disruption of a long distance regulatory region upstream of SOX9 in isolated disorders of sex development. J. Med. Genet. 48, 825-830 (2011
63. Arboleda, V.A. et al. Targeted massively parallel sequencing provides comprehensive genetic diagnosis for patients with disorders of sex development. Clin. Genet. 83, 35-43 (2013
64. Bashamboo, A. et al. Mutations in the FOG2/ZFPM2 gene are associated with anomalies of human testis determination. Hum. Mol. Genet. 23, 3657-3665 (2014
65. Callier, P. et al. Loss of function mutation in the palmitoyl-transferase HHAT leads to syndromic 46, XY disorder of sex development by impeding Hedgehog protein palmitoylation and signaling. PLoS Genet. 10, e1004340 (2014
66. Eggers, S. et al. Whole exome sequencing combined with linkage analysis identifies a novel 3 bp deletion in NR5A1. Eur. J. Hum. Genet. 23, 486-93 (2015
67. Auchus, R.J. & Miller, W.L. Defects in androgen biosynthesis causing 46, XY disorders of sexual development. Semin. Reprod. Med. 30, 417-426 (2012
68. Khattab, A. et al. Pitfalls in hormonal diagnosis of 17-β hydroxysteroid dehydrogenase III deficiency. J. Pediatr. Endocrinol. Metab. http: //dx.doi.org/10.1515/jpem-2014-0295
69. Wu, J.Y. et al. A novel NR5A1 variant in an infant with elevated testosterone from an Australasian cohort of 46, XY patients with disorders of sex development. Clin. Endocrinol. (Oxf.) 78, 545-550 (2013
70. Mendonca, B.B., Domenice, S., Arnhold, I.J. & Costa, E.M. 46, XY disorders of sex development (DSD). Clin. Endocrinol. (Oxf.) 70, 173-187 (2009
71. Hughes, I.A. et al. Androgen insensitivity syndrome. Lancet 380, 1419-1428 (2012
72. Melo, K.F. et al. Clinical, hormonal, behavioral, and genetic characteristics of androgen insensitivity syndrome in a Brazilian cohort: five novel mutations in the androgen receptor gene. J. Clin. Endocrinol. Metab. 88, 3241-3250 (2003
73. Jaaskelainen, J. Molecular biology of androgen insensitivity. Mol. Cell. Endocrinol. 352, 4-12 (2011
74. Hughes, I.A. & Deeb, A. Androgen resistance. Best Pract. Res. Clin. Endocrinol. Metab. 20, 577-598 (2006
75. Robyr, D., Wolffe, A.P. & Wahli, W. Nuclear hormone receptor coregulators in action: diversity for shared tasks. Mol. Endocrinol. 14, 329-347 (2000
76. Weng, Y. et al. Analysis of testosterone and dihydrotestosterone in mouse tissues by liquid chromatography-electrospray ionization-tandem mass spectrometry. Anal. Biochem. 402, 121-128 (2010
77. Shiraishi, S. et al. Simultaneous measurement of serum testosterone and dihydrotestosterone by liquid chromatography-tandem mass spectrometry. Clin. Chem. 54, 1855-1863 (2008
78. Hochberg, Z. et al. Clinical, biochemical, and genetic findings in a large pedigree of male and female patients with 5 a-reductase 2 deficiency. J. Clin. Endocrinol. Metab. 81, 2821-2827 (1996
79. Mendonca, B.B. et al. Male pseudohermaphroditism due to steroid 5 a-reductase 2 deficiency. Diagnosis, psychological evaluation, and management. Medicine (Baltimore) 75, 64-76 (1996
80. Hiort, O. et al. Nonisotopic single strand conformation analysis of the 5 a-reductase type 2 gene for the diagnosis of 5 a-reductase deficiency. J. Clin. Endocrinol. Metab. 81, 3415-3418 (1996
81. Thiele, S., Hoppe, U., Holterhus, P.M. & Hiort, O. Isoenzyme type 1 of 5a-reductase is abundantly transcribed in normal human genital skin fibroblasts and may play an important role in masculinization of 5a-reductase type 2 deficient males. Eur. J. Endocrinol. 152, 875-880 (2005
82. Maimoun, L. et al. Undervirilization in XY newborns may hide a 5a-reductase deficiency: report of three new SRD5A2 gene mutations. Int. J. Androl. 33, 841-847 (2010
83. Chan, A.O. et al. Diagnosis of 5a-reductase 2 deficiency: is measurement of dihydrotestosterone essential?. Clin. Chem. 59, 798-806 (2013
84. Cohen-Kettenis, P.T. Gender change in 46, XY persons with 5a reductase 2 deficiency and 17β-hydroxysteroid dehydrogenase 3 deficiency. Arch. Sex. Behav. 34, 399-410 (2005
85. Cassia Amaral, R. et al. Quality of life in a large cohort of adult Brazilian patients with 46, XX and 46, XY disorders of sex development from a single tertiary centre. Clin. Endocrinol. (Oxf.) 82, 274-279 (2015
86. Cassia Amaral, R. et al. Quality of life of patients with 46, XX and 46, XY disorders of sex development. Clin. Endocrinol. (Oxf.) 82, 274-279 (2015
87. Costa, E.M., Domenice, S., Sircili, M.H., Inacio, M. & Mendonca, B.B. DSD due to 5a-reductase 2 deficiency-from diagnosis to long term outcome. Semin. Reprod. Med. 30, 427-431 (2012
88. Hayashi, G. et al. Weight-Adjusted neonatal 17OH-progesterone cutoff levels improve the efficiency of newborn screening for congenital adrenal hyperplasia. Arq. Bras. Endocrinol. Metabol. 55, 632-637 (2012
89. Silveira, E.L. et al. Molecular analysis of CYP21A2 can optimize the follow-up of positive results in newborn screening for congenital adrenal hyperplasia. Clin. Genet. 76, 503-510 (2009
90. Sarafoglou, K., Lorentz, C.P., Otten, N., Oetting, W.S. & Grebe, S.K. Molecular testing in congenital adrenal hyperplasia due to 21a-hydroxylase deficiency in the era of newborn screening. Clin. Genet. 82, 64-70 (2011
91. Forest, M.G., Morel, Y. & David, M. Prenatal treatment of congenital adrenal hyperplasia. Trends Endocrinol. Metab. 9, 284-289 (1998
92. New, M.I., Abraham, M., Yuen, T. & Lekarev, O. An update on prenatal diagnosis and treatment of congenital adrenal hyperplasia. Semin. Reprod. Med. 30, 396-399 (2012
93. David, M. & Forest, M.G. Prenatal treatment of congenital adrenal hyperplasia resulting from 21-hydroxylase deficiency. J. Pediatr. 105, 799-803 (1984
94. Tardy-Guidollet, V. et al. New management strategy of pregnancies at risk of congenital adrenal hyperplasia using fetal sex determination in maternal serum: French cohort of 258 cases (2002-2011). J. Clin. Endocrinol. Metab. 99, 1180-1188 (2014
95. New, M.I. et al. Noninvasive prenatal diagnosis of congenital adrenal hyperplasia using cell-free fetal DNA in maternal plasma. J. Clin. Endocrinol. Metab. 99, E1022-E1030 (2014
96. New, M.I. et al. Prenatal diagnosis for congenital adrenal hyperplasia in 532 pregnancies. J. Clin. Endocrinol. Metab. 86, 5651-5657 (2001
97. Hirvikoski, T. et al. Cognitive functions in children at risk for congenital adrenal hyperplasia treated prenatally with dexamethasone. J. Clin. Endocrinol. Metab. 92, 542-548 (2007
98. Speiser, P.W. et al. Congenital adrenal hyperplasia due to steroid 21-hydroxylase deficiency: an Endocrine Society clinical practice guideline. J. Clin. Endocrinol. Metab. 95, 4133-4160 (2010
99. Wudy, S.A., Hartmann, M.F., Draper, N., Stewart, P.M. & Arlt, W. A male twin infant with skull deformity and elevated neonatal 17-hydroxyprogesterone: a prismatic case of P450 oxidoreductase deficiency. Endocr. Res. 30, 957-964 (2004
100. Johannsen, T.H. et al. Delayed diagnosis of congenital adrenal hyperplasia with salt wasting due to type II 3β-hydroxysteroid dehydrogenase deficiency. J. Clin. Endocrinol. Metab. 90, 2076-2080 (2005
101. Nordenstrom, A., Forest, M.G. & Wedell, A. A case of 3β-hydroxysteroid dehydrogenase type II (HSD3B2) deficiency picked up by neonatal screening for 21-hydroxylase deficiency: difficulties and delay in etiologic diagnosis. Horm. Res. 68, 204-208 (2007
102. Jeandron, D.D. & Sahakitrungruang, T. A novel homozygous Q334X mutation in the HSD3B2 gene causing classic 3β-hydroxysteroid dehydrogenase deficiency: an unexpected diagnosis after a positive newborn screen for 21-hydroxylase deficiency. Horm. Res. Paediatr. 77, 334-338 (2012
103. Scott, R.R., Gomes, L.G., Huang, N., Van Vliet, G. & Miller, W.L. Apparent manifesting heterozygosity in P450 oxidoreductase deficiency and its effect on coexisting 21-hydroxylase deficiency. J. Clin. Endocrinol. Metab. 92, 2318-2322 (2007
104. Ergun-Longmire, B. et al. Clinical, hormonal and cytogenetic evaluation of 46, XX males and review of the literature. J. Pediatr. Endocrinol. Metab. 18, 739-748 (2005
105. Fechner, P.Y. et al. The role of the sex-determining region Y gene in the etiology of 46, XX maleness. J. Clin. Endocrinol. Metab. 76, 690-695 (1993
106. Ferguson-Smith, M.A. X Y chromosomal interchange in the aetiology of true hermaphroditism and of XX Klinefelter's syndrome. Lancet 2, 475-476 (1966
107. Maciel-Guerra, A.T. et al. XX maleness and XX true hermaphroditism in SRY-negative monozygotic twins: additional evidence for a common origin. J. Clin. Endocrinol. Metab. 93, 339-343 (2008
108. Cox, J.J., Willatt, L., Homfray, T. & Woods, C.G. A SOX9 duplication and familial 46, XX developmental testicular disorder. N. Engl. J. Med. 364, 91-93 (2011
109. Tomaselli, S. et al. Solution structure of the supramolecular adduct between a liver cytosolic bile acid binding protein and a bile acid-based gadolinium(III)-chelate, a potential hepatospecific magnetic resonance imaging contrast agent. J. Med. Chem. 51, 6782-6792 (2008
110. Moalem, S. et al. XX male sex reversal with genital abnormalities associated with a De novo SOX3 gene duplication. Am. J. Med. Genet. A 158A, 1759-1764 (2012
111. Lonardo, F. et al. Prenatal diagnosis of 46, XX testicular DSD. Molecular, cytogenetic, molecular-cytogenetic, and ultrasonographic evaluation. Prenat. Diagn. 29, 998-1001 (2009
112. Ledig, S., Hiort, O., Wunsch, L. & Wieacker, P. Partial deletion of DMRT1 causes 46, XY ovotesticular disorder of sexual development. Eur. J. Endocrinol. 167, 119-124 (2012
113. Ostrer, H. 46, XY disorder of sex development and 46, XY complete gonadal dysgenesis. GeneReviews [online], http: //www.ncbi.nlm.nih.gov/books/NBK1547/(2009
114. Dickerson, C. An overview of prenatal genetic screening and diagnostic testing. NC Med. J. 74, 518-521 (2013
115. McPherson, E. Genetic diagnosis and testing in clinical practice. Clin. Med. Res. 4, 123-129 (2006